[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"The University of Texas Health Science Center, Houston\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":614},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,186,0,25,[9,44,64,90,119,145,176,201,227,252,277,299,322,348,371,398,418,442,462,482,504,527,551,574,594],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":12,"sex":16,"minAge":4,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100648599","trial-of-device-that-is-not-approved-or-cleared-by-the-us-fda-100648599",false,"NCT07721662","Skin-to-skin Care Using the Skincubator: Feasibility and Safety Trial","Inclusion Criteria:\n\n-Extremely preterm (EP) and preterm (PT) infants born between 24 0\u002F7 and 30 6\u002F7 weeks' gestational age (GA)\n\nExclusion Criteria:\n\n* Birth weight \\> 2kg.\n* Hemodynamic instability, defined as new or escalating inotropic support within 12 hours prior to randomization\n* Chest tube in place at time of enrollment.\n* Oxygenation failure, defined as persistent preductal oxygen saturation \\\u003C 85% despite 100% fraction of inspired oxygen (FiO2).\n* Recurrent apnea, requiring bag-mask ventilation more than twice within the 12 hours prior to randomization\n* Known or suspected congenital anomalies or genetic conditions, including Trisomy 13, 18, 21 or cystic fibrosis Multiple gestation, including twins or higher-order multiples\n* Determination by the attending neonatologist that participation is not safe for a given infant","ALL","6 Days",{"count":19,"type":20},60,"ESTIMATED","INTERVENTIONAL",[23],"NA","The purpose of this study is to assess the impact of the Skincubator on average daily duration of Skin-to-skin Care (SSC), to assess the safety of Skincubator-supported SSC during NICU hospitalization, to evaluate feasibility and acceptability of the Skincubator among parents and clinical staff using the Acceptability of Intervention Measure (AIM) implementation framework to assess thermal stability during Skincubator-supported SSC and to assess changes in parental stress associated with Skincubator use during NICU hospitalization.",[26],"Skin to Skin Care for Preterm Infants",[28,29,30],"skin to skin care","pre term infant","skincubator","RECRUITING","2026-08-19",{"date":34,"type":35},"2026-08-21","ACTUAL",{"date":37,"type":35},"2026-07-13",{"date":39,"type":20},"2027-12-31",{"name":41,"class":42},"The University of Texas Health Science Center, Houston","OTHER",1,{"id":45,"slug":46,"hasResults":12,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":12,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":21,"phases":54,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":59,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":63,"locationsCount":43},"100609392","vibrant-capsule-for-spinal-cord-injury-neurogenic-bowel-dysfunction-100609392","NCT07213986","Vibrant Capsule for Spinal Cord Injury Neurogenic Bowel Dysfunction","Pilot Trial of the Vibrant Capsule for Spinal Cord Injury Neurogenic Bowel Dysfunction","Inclusion Criteria:\n\n* Individuals with chronic spinal cord injury (SCI) of more than one year.\n* Stable neurological level and function of SCI for at least six months.\n* Consistent bowel program without changes for at least 3 months.\n* At least one scheduled bowel movement (BM) every three days.\n* Use of digital stimulation, suppositories, enemas, or mini enemas, as part of the scheduled bowel program.\n* Use of oral medications as part of the bowel program.\n\nExclusion Criteria:\n\n* Bowel incontinence occurring more than once per week.\n* Non-English-speaking individuals.\n* History of bowel obstruction, ileus, diverticulitis, or bowel surgery for a disease (appendix removal is ok).\n* Persistent autonomic dysreflexia (AD) triggered by bowel movements.\n* Recent changes to spasticity medications within the past month.\n* History of significant gastrointestinal disorders\n* History of Zenker's diverticulum\n* Dysphagia\n* Esophageal stricture\n* Eosinophilic esophagitis or achalasia\n* Pregnancy.\n* Presence of implanted devices that could be affected by proximity to a direct current magnetic field.","21 Years",{"count":53,"type":20},12,[23],"The goal of this study is to test the safety and effectiveness of Vibrant capsules in spinal cord injury patients with neurogenic bowel.",[57,58],"Neurogenic Bowel Dysfunction","Spinal Cord Injury",{"date":34,"type":35},{"date":61,"type":35},"2026-01-06",{"date":32,"type":20},{"name":41,"class":42},{"id":65,"slug":66,"hasResults":12,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":4,"eligibilityCriteria":70,"healthyVolunteers":12,"sex":16,"minAge":71,"maxAge":72,"enrollmentInfo":73,"targetDuration":4,"studyType":21,"phases":75,"briefSummary":76,"conditions":77,"keywords":79,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":43},"100652938","effect-of-a-femoral-venting-hole-on-embolic-load-in-prophylactic-intramedullary-nailing-100652938","NCT07778238","Effect of a Femoral Venting Hole on Embolic Load in Prophylactic Intramedullary Nailing","Effect of a Femoral Venting Hole on Embolic Load in Prophylactic Intramedullary Nailing: A Feasibility Study","Inclusion Criteria:\n\n* Diagnosis of an impending femur fracture requiring prophylactic intramedullary fixation\n* Impending fracture secondary to a pathologic process, including:\n\n  * Long-term bisphosphonate use, or\n  * Oncologic disease without radiographic evidence of cortical disruption\n* Ability to provide informed consent\n\nExclusion Criteria:\n\n* Inability to obtain adequate intraoperative transthoracic echocardiography (TTE) imaging windows for visualization of right-sided cardiac structures\n* Inability to tolerate or safely undergo TTE monitoring per anesthesia determination\n* Any intraoperative technical limitation preventing reliable echocardiographic data acquisition","18 Years","100 Years",{"count":74,"type":20},10,[23],"The purpose of this study is to measure intraoperative embolic burden during prophylactic intramedullary nailing of impending femur fractures in patients treated with versus without venting, to find the association between embolic burden and intraoperative physiologic changes, measured using standard anesthesia monitors and charted data, to measure Immediate and short-term cardiopulmonary outcomes assessed during hospitalization and to assess procedure-related complications associated with venting",[78],"Femur Fracture",[80,81],"prophylactic intramedullary fixation","femoral vent holes","NOT_YET_RECRUITING","2026-08-17",{"date":34,"type":35},{"date":86,"type":20},"2026-09-01",{"date":88,"type":20},"2027-08-01",{"name":41,"class":42},{"id":91,"slug":92,"hasResults":12,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":12,"sex":16,"minAge":97,"maxAge":98,"enrollmentInfo":99,"targetDuration":4,"studyType":21,"phases":101,"briefSummary":103,"conditions":104,"keywords":106,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":118},"100455677","phase-4-de-implementing-inhaled-nitric-oxide-for-congenital-diaphragmatic-hernia-100455677","NCT05213676","De-implementing Inhaled Nitric Oxide for Congenital Diaphragmatic Hernia","Inhaled Nitric Oxide (iNO) for Congenital Diaphragmatic Hernia (CDH) - The \"NoNO Trial\" - a Multi-center, De-implementation, Stepped-wedge, Cluster-randomized Trial Within an Established Collaborative","Inclusion Criteria:\n\n* Postnatal, live born neonates with CDH\n\n  a. Presence of associated or additional anomalies is acceptable for inclusion\n* Bochdalek hernia location (right or left)\n* Diagnosed prior to 1 month of life\n* Born within or transferred to (within 1 week of life) a CDHSG member center participating in the trial\n\nExclusion Criteria:\n\n* CDH diagnosis after 1 month of age\n* Morgagni diaphragmatic hernia (central \u002F anterior-medial diaphragmatic defect location)\n* Transferred to a CDH Study Group (CDHSG) member center after 1 week of life\n* Patients without potential access to iNO","0 Months","1 Month",{"count":100,"type":20},600,[102],"PHASE4","The purpose of this study is to determine if de-implementation of inhaled nitric oxide (iNO) in the post-natal resuscitation\u002Fstabilization phase affects the composite outcome of extracorporeal life support (ECLS) use and\u002For mortality, as well as ECLS use, mortality, and\u002For oxygenation in congenital diaphragmatic hernia (CDH) newborns and to establish the cost-effectiveness of de-implementing iNO as a therapy in the postnatal resuscitation\u002Fstabilization phase of CDH management, which will be assessed as the incremental health system costs (savings) per prevented ECLS use and\u002For death.",[105],"Congenital Diaphragmatic Hernia",[107,108,109],"CDH","Inhaled Nitric Oxide","Pulmonary Hypertension","2026-08-14",{"date":112,"type":35},"2026-08-18",{"date":114,"type":35},"2025-11-01",{"date":116,"type":20},"2031-04-30",{"name":41,"class":42},19,{"id":120,"slug":121,"hasResults":12,"nctId":122,"briefTitle":123,"officialTitle":123,"acronym":4,"eligibilityCriteria":124,"healthyVolunteers":12,"sex":16,"minAge":71,"maxAge":125,"enrollmentInfo":126,"targetDuration":4,"studyType":21,"phases":128,"briefSummary":129,"conditions":130,"keywords":132,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":43},"100652313","enhancing-brain-connectivity-in-schizophrenia-through-neuromodulation-study-3-100652313","NCT07772349","Enhancing Brain Connectivity in Schizophrenia Through Neuromodulation (Study 3)","Inclusion Criteria:\n\n1. Male and female ages between ages 18-60 years\n2. Ability to give written informed consent (age 18 or above)\n3. Diagnosed with schizophrenia-spectrum disorder and Evaluation to Sign Consent (ESC) above 10.\n\nExclusion Criteria:\n\n1. Inability to sign informed consent.\n2. Any history of seizures.\n3. Any acute and unstable major medical illnesses that may affect normal brain functioning. Examples of these conditions include, but not limited to, recent stroke, seizure, history of significant head trauma, CNS infection or tumor, other significant brain neurological conditions (As this is a study of medical comorbidity, most medical conditions, once stable, are not exclusion criteria).\n4. Taking \\> 400 mg clozapine\u002Fday and not on anti-seizure medication(s) with sufficient dose.\n5. Failed TMS screening questionnaire.\n6. Significant alcohol or other drug use (substance abuse within 1 month or substance dependence history within 6 months and having substance usage within 1 month) other than nicotine or marijuana dependence.\n7. A history of thrombosis, family history of thrombosis, or medical conditions that may lead to a hypercoagulable state (increased chance to develop blood clots)\n8. Woman who is pregnant (child-bearing potential but not on contraceptive and missing menstrual period; or by self-report; or by positive urine pregnancy test).\n9. History of head injury with loss of consciousness over 10 minutes; history of brain surgery\n10. Cannot refrain from using alcohol and\u002For marijuana 24 hours or more prior to experiments.\n11. Students and employees currently involved with our lab (lab employees and personnel will be excluded from the study to avoid possible coercion or possible appearance of coercion, or chance of breach of privacy and confidentiality).\n12. For MRI, unable to undergo MRI scanning due to metallic devices or objects (cardiac pacemaker or neurostimulator, some artificial joints, metal pins, surgical clips, or other implanted metal parts) or claustrophobic to the scanner.","60 Years",{"count":127,"type":20},120,[23],"The aim of the study is to assess the treatment effects of deep active repetitive transcranial magnetic stimulation (rTMS) with H4 coil combined with cognitive training for improving frontal white matter microstructural integrity in patients with schizophrenia spectrum disorder (SSD).",[131],"Schizophrenia",[133,134,135,136,137],"Transcranial magnetic stimulation","schizophrenia","white matter","connectivity","myelination","2026-08-13",{"date":32,"type":35},{"date":141,"type":20},"2026-10-01",{"date":143,"type":20},"2029-05-01",{"name":41,"class":42},{"id":146,"slug":147,"hasResults":12,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":4,"eligibilityCriteria":151,"healthyVolunteers":12,"sex":16,"minAge":71,"maxAge":4,"enrollmentInfo":152,"targetDuration":4,"studyType":21,"phases":154,"briefSummary":155,"conditions":156,"keywords":164,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":170,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":43},"100560208","effect-of-photobiomodulation-on-pain-and-healing-of-the-vertical-releasing-incision-after-endodontic-microsurgery-100560208","NCT06574152","Effect of Photobiomodulation on Pain and Healing of the Vertical Releasing Incision After Endodontic Microsurgery","Effect of Photobiomodulation on Pain and Healing of the Vertical Releasing Incision After Endodontic Microsurgery: A Randomized Clinical Trial","Inclusion Criteria:\n\n* American Society of Anesthesiologists (ASA) I or II.\n* At least one tooth will receive EMS.\n* Flap design that includes at least one VRI (triangular, rectangular, papilla base or submarginal rectangular).\n\nExclusion Criteria:\n\n* ASA III or IV.\n* Current heavy smokers (\\>10 cigarettes\u002Fday)\n* Uncontrolled diabetes (HbA1c ≥ 7%) or other uncontrolled systemic diseases that may comprise healing, such as vitamin C deficiency, neutrophil deficiencies, immunodeficiency syndromes, or leukemia.\n* Surgical access on the palatal surface.\n* Acute swelling or abscess present on the day of the surgery.\n* Any event or condition that would make continued participation in the study not in the best interest of the subject, as determined by the investigator.\n* Pregnancy.\n* Development of any medical condition that might affect the treatment and clinical outcomes, as determined by the investigator.\n* Initiation of any treatment or exposure that might affect therapy's healing, as determined by the investigator.",{"count":153,"type":20},90,[23],"The purpose of this study is to evaluate the effect of Photobiomodulation (PBM) in postoperative pain after endodontic microsurgery (EMS) in patients from the University of Texas Health Science Center at Houston, School of Dentistry Graduate Endodontic Clinic and to assess the soft tissue healing of the vertical releasing incision (VRI) after PBM",[157,158,159,160,161,162,163],"Apical Periodontitis","Endodontically Treated Teeth","Endodontic Disease","Apical Cyst","Apical Granuloma","Periradicular Disease","Previous Endodontic Treatment",[165,166,167,168,169],"vertical incision","photobiomodulation","apicoectomy","endodontic microsurgery","laser therapy",{"date":83,"type":35},{"date":172,"type":35},"2024-08-20",{"date":174,"type":20},"2028-05-04",{"name":41,"class":42},{"id":177,"slug":178,"hasResults":12,"nctId":179,"briefTitle":180,"officialTitle":181,"acronym":4,"eligibilityCriteria":182,"healthyVolunteers":12,"sex":16,"minAge":71,"maxAge":4,"enrollmentInfo":183,"targetDuration":4,"studyType":21,"phases":185,"briefSummary":186,"conditions":187,"keywords":189,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":200,"locationsCount":43},"100652239","phase-4-a-pragmatic-trial-of-interleukin-17-inhibition-versus-janus-kinase-inhibition-after-tumor-necrosis-factor-alpha-inhibitor-failure-in-axial-spondyloarthritis-100652239","NCT07770646","A Pragmatic Trial of Interleukin-17 Inhibition Versus Janus Kinase Inhibition After Tumor Necrosis Factor-alpha Inhibitor Failure in Axial Spondyloarthritis","A Pragmatic Randomized Pilot Trial of Interleukin-17 Inhibition Versus Janus Kinase Inhibition After Tumor Necrosis Factor-alpha Inhibitor Failure in Axial Spondyloarthritis","Inclusion Criteria:\n\n* fulfill ASAS classification criteria for axSpA and\u002For modified New York classification criteria for AS\n* Active axSpA (ASDAS ≥ 2.1 and\u002For BASDAI ≥ 4)\n* Failure of or intolerance to ≥1 TNF\n* Participants of reproductive potential must agree to use any form of effective contraception during the study period, in accordance with standard clinical practice and FDA labeling for the assigned study medication\n* Ability to provide informed consent\n\nExclusion Criteria:\n\n* Previously received an IL-17i or JAKi\n* Active infection requiring antimicrobials\n* Contraindications to either treatment arm:\n\n  * Inflammatory bowel disease (IBD)- Crohn's disease or Ulcerative Colitis\n  * Active cancer or cancer remission within the past 3 years (apart from non-melanoma skin cancer (NMSC) and cervical intraepithelial neoplasia (CIN)\n  * History of stroke, heart attack, or blood clots (venous or arterial)\n  * Cirrhosis\n  * End-stage renal disease (GFR \\\u003C15) or dialysis\n  * Human Immunodeficiency Virus (HIV) positive\n  * Pregnant or lactating\n* Concomitant use of other biologic or targeted synthetic disease-modifying anti-rheumatic drug (tsDMARD) therapy",{"count":184,"type":20},40,[102],"The purpose of this study is to determine the feasibility of conducting a pragmatic trial of IL-17i versus JAKi in adults with axial spondyloarthritis (axSpA) who have failed at least one tumor necrosis factor-alpha inhibitor (TNFi), to estimate the effectiveness of IL-17i versus JAKi at 16 weeks and to determine additional effectiveness measures, safety, and treatment persistence of IL-17i versus JAKi",[188],"Axial Spondyloarthritis (AxSpA)",[190,191,192,193],"comparative effectiveness","axial spondyloarthritis","secukinumab","upadacitinib","2026-08-12",{"date":112,"type":35},{"date":197,"type":20},"2026-09-14",{"date":199,"type":20},"2029-09-15",{"name":41,"class":42},{"id":202,"slug":203,"hasResults":12,"nctId":204,"briefTitle":205,"officialTitle":205,"acronym":4,"eligibilityCriteria":206,"healthyVolunteers":12,"sex":16,"minAge":207,"maxAge":208,"enrollmentInfo":209,"targetDuration":4,"studyType":21,"phases":210,"briefSummary":212,"conditions":213,"keywords":217,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":221,"startDateStruct":222,"completionDateStruct":224,"leadSponsor":226,"locationsCount":43},"100570360","phase-2-acceptability--safety-of-two-sequential-doses-of-psilocybin-in-bipolar-disorder-ii-depression-and-suicidality-100570360","NCT06706232","Acceptability & Safety of Two Sequential Doses of Psilocybin in Bipolar Disorder II Depression and Suicidality","Inclusion Criteria:\n\n* Must have completed written informed consent\n* Must be at 25 years of age or older at screening (but below age of 70)\n* Confirmed Diagnostic and Statistical Manual of Mental Disorders (DSM-5) diagnosis of BD-II using clinical records and Diagnostic Interview for Anxiety, Mood, and Obsessive-compulsive disorder (OCD) and Related Neuropsychiatric Disorders (DIAMOND)\n* Must meet criteria for suicidality according to the INQ cutoff scores: A score of at least 12 on the Perceived Burden (PB) subscale and at least a score of 36 on the Thwarted Belongingness (TB) subscale indicating substantial risk for passive suicidal ideation\n* Must meet criteria for depression according to the MADRS cutoff scores: A score of 7-34 indicating mild to moderate depression\n* Must pass medical examination (physical exam, personal\u002Ffamily medical history, including consultation with current medical provider, ECG, about 4 tablespoons blood draw, psychiatric\u002Fpsychological assessments, urine drug test)\n* Willingness to taper down mood stabilizers and other relevant medications (including but not limited to: antidepressants, antipsychotics, lithium, benzodiazepines, Monoamine oxidase inhibitors (MAOIs), Selective serotonin reuptake inhibitors (SSRIs), Serotonin and norepinephrine reuptake inhibitors (SNRIs), A serotonin-norepinephrine-dopamine reuptake inhibitors (SNDRIs), Tricyclic antidepressants (TCAs), stimulants, cannabis, and other medications, supplements or therapeutics that affect serotonergic function) for the duration of the study before and during administration days (starting 5 weeks before administration), and be off medication for at least 2 weeks prior to administration\n* Willingness to stop allowed medication at least 24 h prior to administration of psilocybin as advised by study physician (e.g., benzodiazepines)\n* Ability to complete all protocol required assessment tools without any assistance or alteration to the copyrighted assessments, and to comply with all study visits\n\nExclusion Criteria:\n\n* Participants who do not read\u002Fspeak English\n* Active suicidal ideation with at least some intent and\u002For plan (i.e., a current score of 4 or 5 on the C-SSRS)\n* History of medically significant suicide attempt in the last 6 months\n* Current or past history of Bipolar I disorder, psychotic symptoms or psychotic disorder, (including but not limited to schizophrenia, delusional disorder, schizoaffective disorder) clinically relevant personality disorder (such as borderline, antisocial, narcissistic or paranoid personality disorder), or any serious psychiatric comorbidity considered negatively impacting participation or safety (e.g., PTSD or severe substance use or alcohol disorder) assessed by medical history and\u002For a structured clinical interview\n* Have a first or second degree relative with Bipolar I disorder or a psychotic disorder\n* Currently experiencing a hypomanic or mixed-symptom episode\n* Have a psychiatric or other condition judged to be incompatible with establishment of rapport or safe exposure to psilocybin\n* Any indication of a Personality Disorder (PD) such as but not limited to Borderline, Narcissistic, Antisocial, Paranoid, or Schizotypal PD based on Structured Clinical Interview for DSM-5 for PD and\u002For clinical judgment","25 Years","70 Years",{"count":74,"type":20},[211],"PHASE2","The purpose of the study is to assess the safety and acceptability of up to two sequential administrations of 25 mg psilocybin with additional therapeutic support in decreasing suicidality in patients with Bipolar Disorder (BD II) depression.",[214,215,216],"Bipolar II Disorder","Depression, Bipolar","Suicidality",[218,219],"Bipolar II Depression","Psilocybin","2026-08-11",{"date":194,"type":35},{"date":223,"type":35},"2025-07-07",{"date":225,"type":20},"2027-08",{"name":41,"class":42},{"id":228,"slug":229,"hasResults":12,"nctId":230,"briefTitle":231,"officialTitle":232,"acronym":4,"eligibilityCriteria":233,"healthyVolunteers":12,"sex":16,"minAge":71,"maxAge":72,"enrollmentInfo":234,"targetDuration":4,"studyType":21,"phases":236,"briefSummary":238,"conditions":239,"keywords":241,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":245,"lastUpdatePostDateStruct":246,"startDateStruct":247,"completionDateStruct":249,"leadSponsor":250,"locationsCount":251},"100651171","phase-1-photodynamic-therapy-for-onychomycosis-100651171","NCT07756671","Photodynamic Therapy For Onychomycosis","Photodynamic Therapy For Onychomycosis: An Open Label Study","Inclusion Criteria:\n\n* Clinical and mycological diagnosis \\[by potassium hydroxide (KOH) stain\\] of onychomycosis\n\nExclusion Criteria:\n\n* Known or suspected allergies or sensitivities to any components of any of the study drugs\n* Patients with coagulation disorders\n* Known or suspected claustrophobia\n* Pregnancy during the treatment period\n* Medically unable to consent\n* Employees of the clinics\n* Prisoners",{"count":235,"type":20},5,[237],"PHASE1","The purpose of this study is clinical and mycological clearance of onychomycosis using photodynamic therapy (PDT) with aminolevulinic acid (ALA) 10% gel at 6 months, 3 months, 9 months and 12 months",[240],"Onychomycosis of Toenail",[242,243,244],"toenail fungus","photodynamic therapy (PDT)","aminolevulinic acid (ALA)","2026-08-06",{"date":220,"type":35},{"date":248,"type":20},"2026-08-10",{"date":39,"type":20},{"name":41,"class":42},3,{"id":253,"slug":254,"hasResults":12,"nctId":255,"briefTitle":256,"officialTitle":257,"acronym":258,"eligibilityCriteria":259,"healthyVolunteers":12,"sex":16,"minAge":260,"maxAge":261,"enrollmentInfo":262,"targetDuration":4,"studyType":21,"phases":264,"briefSummary":265,"conditions":266,"keywords":268,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":245,"lastUpdatePostDateStruct":270,"startDateStruct":271,"completionDateStruct":273,"leadSponsor":275,"locationsCount":276},"100546815","humidity-in-incubators-for-tiny-infants-100546815","NCT06399861","Humidity in Incubators for Tiny Infants","Humidity in Incubators for Tiny Infants (HumidITI) Trial (Stage 1)","HumidITI","Inclusion Criteria:\n\n* Inborn infant of \\\u003C25 weeks' gestation admitted to the NICU\n\nExclusion Criteria:\n\n* Infants with known congenital skin conditions\n* Outborn infants\n* Infants with unknown gestational age prior to birth","0 Days","1 Day",{"count":263,"type":20},300,[23],"The objective of the study is to assess 2 different initial incubator humidification protocols for infants \\\u003C25 weeks' gestation admitted to the neonatal intensive care unit (NICU). The hypothesis is that a higher starting humidity decreases dehydration and results in no difference in survival or morbidity. Higher (90%) and lower (70%) starting humidity will be compared.",[267],"Extremely Premature Infant",[269],"Humidification Protocol",{"date":248,"type":35},{"date":272,"type":35},"2024-06-25",{"date":274,"type":20},"2027-07-01",{"name":41,"class":42},9,{"id":278,"slug":279,"hasResults":12,"nctId":280,"briefTitle":281,"officialTitle":281,"acronym":4,"eligibilityCriteria":282,"healthyVolunteers":12,"sex":16,"minAge":71,"maxAge":125,"enrollmentInfo":283,"targetDuration":4,"studyType":21,"phases":284,"briefSummary":285,"conditions":286,"keywords":288,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":291,"lastUpdatePostDateStruct":292,"startDateStruct":294,"completionDateStruct":296,"leadSponsor":298,"locationsCount":43},"100597559","bilateral-prefrontal-and-insular-tms-for-depression-in-schizophrenia-100597559","NCT07060066","Bilateral Prefrontal and Insular TMS for Depression in Schizophrenia","Inclusion Criteria:\n\n* Male and female ages between ages 18-60 years.\n* Ability to give written informed consent (age 18 or above).\n* Diagnosed with schizophrenia-spectrum disorder and Evaluation to Sign Consent (ESC) above 10.\n* Score of Calgary depression scale for schizophrenia (CDSS) ≥ 3.\n\nExclusion Criteria:\n\n* Inability to sign informed consent.\n* Any major medical illnesses that may affect normal brain functioning. Examples of these conditions include, but are not limited to: stroke, repeated seizure, history of significant head trauma with cognitive sequela, CNS infection or tumor, other significant brain neurological conditions.\n* Significant alcohol or other drug use other than nicotine or marijuana dependence.\n* Inability to refrain from using alcohol and\u002For marijuana 24 hours or more prior to experiments.\n* Pregnancy, as classified by a woman of child-bearing potential who is not using a contraceptive and has missed a menstrual period; or by self-report; or by positive urine pregnancy test.\n* For MRI, inability to participate in the MRI scanning due to metallic devices or objects (cardiac pacemaker or neurostimulator, some artificial joints, metal pins, surgical clips or other implanted metal parts) or declining to get in the scanner.\n* Failed TMS safety questionnaire.",{"count":127,"type":20},[23],"The purpose of this study is to provide an effective repetitive transcranial magnetic stimulation (rTMS) treatment for depressive symptoms in patients with schizophrenia. Schizophrenia patients with depressive symptoms will be exposed to rTMS to improve their symptoms.",[287],"Schizophrenia and Related Disorders",[289,134,290],"transcranial magnetic stimulation","depression","2026-08-04",{"date":293,"type":35},"2026-08-05",{"date":295,"type":35},"2025-10-23",{"date":297,"type":20},"2030-06-01",{"name":41,"class":42},{"id":300,"slug":301,"hasResults":12,"nctId":302,"briefTitle":303,"officialTitle":303,"acronym":304,"eligibilityCriteria":305,"healthyVolunteers":12,"sex":16,"minAge":71,"maxAge":4,"enrollmentInfo":306,"targetDuration":4,"studyType":21,"phases":308,"briefSummary":309,"conditions":310,"keywords":312,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":316,"lastUpdatePostDateStruct":317,"startDateStruct":318,"completionDateStruct":319,"leadSponsor":321,"locationsCount":43},"100638764","delivery-of-a-culturally-tailored-exercise-training-intervention-for-hispanics-with-multiple-sclerosis-100638764","NCT07606742","Delivery of a Culturally Tailored Exercise Training Intervention for Hispanics With Multiple Sclerosis","VAMOS-MS","Inclusion Criteria:\n\n* diagnosis of MS\n* relapse-free in the past 30 days\n* self-identify as Hispanic\u002FLatino\n* Patient Determined Disease Steps Scale (PDDS) score between 3.0 (gait disability) and 6.0 (bilateral support) indicates walking disability.\n* MSWS-12 score between 25 and 75, indicating walking disability\n* Willingness to complete the questionnaires and undergo randomization\n* English or Spanish as a primary language\n\nExclusion Criteria:\n\n* significant exercise-related risk factors or contraindications, assessed individually using the Physical Activity Readiness Questionnaire (PAR-Q; requires clearance from physician).",{"count":307,"type":20},66,[23],"The purpose of this study is to establish differences in the primary outcome of walking dysfunction using the 12-Item Multiple Sclerosis Walking Scale (MSWS-12) and to establish differences in the secondary outcome of HRQoL using the 29-Item Multiple Sclerosis Walking Scale (MSWS-29) between the exercise training intervention condition and the waitlist control condition following the 16-week intervention period.",[311],"Multiple Sclerosis",[313,314,315],"Exercise training","mobility disability","implementation","2026-08-03",{"date":245,"type":35},{"date":86,"type":20},{"date":320,"type":20},"2028-10-31",{"name":41,"class":42},{"id":323,"slug":324,"hasResults":12,"nctId":325,"briefTitle":326,"officialTitle":327,"acronym":328,"eligibilityCriteria":329,"healthyVolunteers":12,"sex":16,"minAge":330,"maxAge":331,"enrollmentInfo":332,"targetDuration":4,"studyType":21,"phases":334,"briefSummary":335,"conditions":336,"keywords":339,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":316,"lastUpdatePostDateStruct":342,"startDateStruct":343,"completionDateStruct":345,"leadSponsor":347,"locationsCount":43},"100586443","phase-2-lipid-infusions-to-optimize-nutrition-trial-100586443","NCT06915441","Lipid Infusions to Optimize Nutrition Trial","Lipid Infusions to Optimize Nutrition (LION) and Minimize Bronchopulmonary Dysplasia and Neurodevelopmental Impairment in Extremely Preterm Infants: A Randomized Comparative Effectiveness Trial","LION","Inclusion Criteria:\n\n* inborn \\\u003C28 weeks gestational age (GA) or ≤1000g birth weight (BW)\n* survives until 12 hours after birth.\n\nExclusion Criteria:\n\n* Infants who are unable to be enrolled by 96 hours postnatal age\n* Major anomaly\n* Overt non-bacterial infection\n* Infants likely to expire soon defined as limiting or withdrawal of intensive care recommended or requested by the parents.","12 Hours","28 Weeks",{"count":333,"type":20},230,[211],"The purpose of this study is to identify survival free of bronchopulmonary dysplasia (BPD), fatty acid profiles, and early biochemical measures for oxidative stress comparing mixed oil lipid emulsion (MOLE) vs soybean oil-based lipid emulsion (SOLE) and to establish whether MOLE or SOLE is more effective in minimizing pulmonary outcomes, neonatal morbidities, long-term morbidity and mortality, and improving discharge growth and Bayley Scales of Infant Development Fourth Edition (BSID-IV) neurodevelopmental assessment at two years",[337,338],"Bronchopulmonary Dysplasia","Neurodevelopmental Impairment",[340,341],"soybean oil-based lipid emulsion (SOLE)","mixed oil lipid emulsion (MOLE)",{"date":245,"type":35},{"date":344,"type":35},"2026-04-29",{"date":346,"type":20},"2030-12-31",{"name":41,"class":42},{"id":349,"slug":350,"hasResults":12,"nctId":351,"briefTitle":352,"officialTitle":353,"acronym":4,"eligibilityCriteria":354,"healthyVolunteers":12,"sex":16,"minAge":71,"maxAge":4,"enrollmentInfo":355,"targetDuration":4,"studyType":21,"phases":357,"briefSummary":358,"conditions":359,"keywords":361,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":364,"lastUpdatePostDateStruct":365,"startDateStruct":366,"completionDateStruct":368,"leadSponsor":370,"locationsCount":43},"100566364","protective-benefits-of-a-clear-liquid-diet-on-residual-gastric-content-in-patients-taking-glucagon-like-peptide-1-receptor-glp-1-ra-agonist-prior-to-anesthesia-100566364","NCT06654219","Protective Benefits of a Clear Liquid Diet on Residual Gastric Content in Patients Taking Glucagon Like Peptide-1 Receptor (GLP-1 RA) Agonist Prior to Anesthesia","Protective Benefits of a Clear Liquid Diet on Residual Gastric Content in Patients Taking Glucagon Like Peptide-1 Receptor Agonist Prior to Anesthesia","Inclusion Criteria:\n\n* Patients taking Glucagon Like Peptide-1 Receptor (GLP-1 RA) agonists\n* Undergoing upper endoscopy only - no colonoscopy due to prep\n\nExclusion Criteria:\n\n* Previous gastric resection or bypass\n* Gastric band in situ\n* Previous fundoplication\n* Large hiatal hernia\n* Pregnant patients\n* Recent trauma\n* Inability to turn to the right lateral decubitus position.\n* Patients on erythromycin, metoclopramide, domperidone, opioids.\n* Gastroparesis previous",{"count":356,"type":20},136,[23],"The purpose of this study is to determine if prolonged fasting from solids and transitioning to a CLD for 24 hours is protective to decrease RGC in patients on GLP-1 RAs presenting for upper endoscopy, to determine if prolonged fasting is associated with increased thirst, hunger and anxiety, To determine if signs and symptoms of nausea, vomiting, retching, abdominal bloating, and abdominal pain are present on the day of surgery, to see if there is any variability between preoperative gastric ultrasound assessment and volume of gastric contents visualized on upper endoscopy, to determine time of gastric emptying by serial Gastric ultrasonography (GUS) scans every 2 hours in subjects who presented with an initial at-risk scan, to determine the choice of anesthesia used based on preoperative GUS results, to determine if there were any adverse events recorded in this study group, to determine if duration of GLP-1 RA therapy has an association with residual gastric content (RGC). and to determine if dosing of GLP-1 RA has an association with RGC.",[360],"Pulmonary Aspiration",[362,363],"Glucagon Like Peptide-1 Receptor (GLP-1 RA)","full stomach","2026-08-01",{"date":291,"type":35},{"date":367,"type":35},"2025-10-30",{"date":369,"type":20},"2026-12-31",{"name":41,"class":42},{"id":372,"slug":373,"hasResults":12,"nctId":374,"briefTitle":375,"officialTitle":376,"acronym":4,"eligibilityCriteria":377,"healthyVolunteers":378,"sex":16,"minAge":379,"maxAge":380,"enrollmentInfo":381,"targetDuration":4,"studyType":21,"phases":383,"briefSummary":384,"conditions":385,"keywords":389,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":392,"lastUpdatePostDateStruct":393,"startDateStruct":394,"completionDateStruct":395,"leadSponsor":397,"locationsCount":43},"100650153","developing-biomarker-supported-schizophrenia-spectrum-disorder-ssd-prevention-100650153","NCT07743645","Developing Biomarker-Supported Schizophrenia Spectrum Disorder (SSD) Prevention","Developing Biomarker-Supported SSD Prevention","Inclusion Criteria:\n\n* Family history of SSD (defined as first-degree (e.g., a parent or a sibling), second-degree (e.g., an uncle or a grandparent), or other combinations of biological relatives in the family have or likely have a diagnosis of SSD or other closely related severe mental illnesses equivalent to at least 25% of genetic sharing) per medical record review and\u002For parent\u002Flegal guardian report and confirmed by a structured interview\n* screening positive for two or more risk factors targeted by the intervention\n* Participants and parent(s)\u002Flegal guardian(s) agree to participate\n* psychiatrically stable and have no major changes in antidepressant, stimulant, or antipsychotic medication in the past 4 weeks.\n\nExclusion Criteria:\n\n* Current or past history of psychotic disorders or clinical high risk for psychosis (CHR-p) per study interview\n* Current or past antipsychotic medication use to specifically treat a psychotic disorder\n* major medical and neurological conditions\n* moderate to severe intellectual disabilities or mild intellectual disabilities but expected to have difficulty completing the study assessments;\n* current drug or alcohol use that impacts functioning and study engagement;\n* Not able to give assent, permission, or consent.\n* Not able to undergo MRI.",true,"9 Years","19 Years",{"count":382,"type":20},100,[23],"The purpose of this study is to compare the effect of a brief family-based psychosocial intervention that addresses modifiable SSD risk factors on persistent and distressing psychotic-like experiences in children and young adults with a family history of SSD and high versus low baseline SSD-like brain patterns",[386,387,388],"Prevention","Risk Factors for Mental Illness","Family History of Schizophrenia Spectrum Disorder",[390,386,391],"Risk Reduction Therapy (RRT)","family history of schizophrenia spectrum disorder","2026-07-30",{"date":291,"type":35},{"date":141,"type":20},{"date":396,"type":20},"2031-04-01",{"name":41,"class":42},{"id":399,"slug":400,"hasResults":12,"nctId":401,"briefTitle":402,"officialTitle":402,"acronym":4,"eligibilityCriteria":403,"healthyVolunteers":12,"sex":16,"minAge":71,"maxAge":404,"enrollmentInfo":405,"targetDuration":4,"studyType":21,"phases":407,"briefSummary":408,"conditions":409,"keywords":410,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":392,"lastUpdatePostDateStruct":412,"startDateStruct":413,"completionDateStruct":415,"leadSponsor":417,"locationsCount":43},"100279394","alternative-stimulation-mode-and-location-for-auditory-hallucination-neuromodulation-treatment-100279394","NCT02916810","Alternative Stimulation Mode and Location for Auditory Hallucination Neuromodulation Treatment","Inclusion Criteria:\n\n* Male and female ages between ages 18-50 years\n* Ability to give written informed consent (age 18 or above)\n* Diagnosed with schizophrenia-spectrum disorder and Evaluation to Sign Consent (ESC) above 10.\n* Is currently under the care of a licensed primary care provider or mental healthcare provider (e.g., psychiatrist, psychologist, nurse practitioner, licensed clinical social worker).\n* Have auditory hallucinations despite treated by two or more antipsychotics including one atypical antipsychotic medication.\n* Agrees to: (a) provide written permission, as requested, to allow any and all forms of communication between the investigators and study staff and any health care provider who currently provides and\u002For has provided service to the subject within two years of study enrollment; and (b) provide the names and verifiable contact information (name, email and mailing address, mobile and land-line phone number, as applicable) of at least two reliable persons ≥ age 22, who reside within a 30-minute drive of the subject's residence, and whom the research staff is at liberty to contact, as deemed necessary, for the duration of study participation.\n\nExclusion Criteria:\n\n* Persons with a first-degree relative with inherited epilepsy, seizure disorder, or seizures or persons who answer \"yes\" to any of the parts (A. - G.) of Question 3 of an epilepsy screening questionnaire.\n* Taking \\> 400 mg clozapine\u002Fday and not on anti-seizure medication(s) with sufficient dose.\n* Failed TMS screening questionnaire.\n* Significant alcohol or other drug use (substance abuse within 1 month or substance dependence history within 6 months and having substance usage within 1 month) other than nicotine or marijuana dependence\n* Any major medical illnesses that may affect normal brain functioning. Examples of these conditions include, but not limited to, stroke, CNS infection or tumor, other significant brain neurological conditions.\n* Cardiac pacemakers, implanted medication pumps, intracardiac lines, or acute, unstable cardiac disease, with intracranial implants (e.g. aneurysm clips, shunts, stimulators, cochlear implants, or electrodes) or any other metal object within or near the head, excluding the mouth, that cannot be safely removed.\n* History of head injury with loss of consciousness over 10 minutes; history of brain surgery\n* Cannot refrain from using alcohol and\u002For marijuana 24 hours or more prior to experiments.\n* Woman who is pregnant (child-bearing potential but not on contraceptive and missing menstrual period; or by self-report; or by positive pregnancy test) or has had unprotected sexual intercourse without birth control in the last 4 weeks.\n* Moderate-High Risk of suicide according to the Columbia - Suicide Severity Rating Scale (C-SSRS) Screen Version - Recent (i.e. answers YES to Question 3 and NO to Question 6 (Moderate risk); or answers YES to Questions 4, 5, or 6 (High risk) or in the clinical judgement of the investigator or the study psychiatrist.\n* In the medical opinion of the investigator, subjects with the following circumstances or conditions which can increase the risk of seizures may be excluded: sleep deprivation; major depressive disorder comorbid with dementia, underweight status; concurrent use of cephalosporins and antiarrhythmics (particularly propranolol); metabolic abnormalities (hyponatremia, hypocalcemia, hypomagnesemia, hypoglycemia, hyperglycemia, renal failure\u002Furemia, liver failure); raised blood concentrations of proconvulsant medications due to reduced clearance (e.g. secondary to initiation of antibiotics for treatment of infections); alcohol withdrawal; use of stimulants, such as cocaine or MDMA; use of immunosuppressive therapy with cyclosporine, tacrolimus and other agents that can cause the posterior reversible leukoencephalopathy syndrome; dialysis; systemic infection, and fever itself.\n* History (or family history) of deep vein thrombosis.","50 Years",{"count":406,"type":20},140,[23],"The purpose of the study is to test the hypothesis that functionally navigated repetitive TMS stimulations to the prefrontal cortex (PFC) modulate aberrant cortical electrical activities at PFC circuitry. The TMS location of the PFC site will be individually localized by the symptom-related functional connectivity between PFC and symptom related areas (such as the auditory and language processing cortex). The investigators predict that such modulation will correct abnormal activities in patients with schizophrenia, reduce symptoms, especially auditory hallucination, and improve working memory\u002Fsustained attention performance.",[287],[289,134,411],"MRI",{"date":316,"type":35},{"date":414,"type":35},"2025-02-01",{"date":416,"type":20},"2029-07-01",{"name":41,"class":42},{"id":419,"slug":420,"hasResults":12,"nctId":421,"briefTitle":422,"officialTitle":423,"acronym":4,"eligibilityCriteria":424,"healthyVolunteers":12,"sex":16,"minAge":425,"maxAge":426,"enrollmentInfo":427,"targetDuration":4,"studyType":21,"phases":428,"briefSummary":429,"conditions":430,"keywords":432,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":435,"lastUpdatePostDateStruct":436,"startDateStruct":438,"completionDateStruct":439,"leadSponsor":441,"locationsCount":43},"100642398","breestim-in-managing-neuropathic-pain-after-spinal-cord-injury-sci-100642398","NCT07659743","BreEStim in Managing Neuropathic Pain After Spinal Cord Injury (SCI)","A Randomized, Double-blind, Sham-controlled, Parallel-group Trial Designed to Evaluate the Efficacy of BreEStim in Managing Neuropathic Pain After Spinal Cord Injury (SCI)","Inclusion Criteria:\n\n* has a history of SCI \\> 1 year\n* has a DN4 (Douleur Neuropathique en 4 Questions) score of 4 or greater\n* has neuropathic pain \\>3 months\n* is stable on oral pain medications at least one month\n* Able to tolerate BreEStim treatment for 1 minute\n\nExclusion Criteria:\n\n* is on a mechanical ventilator\n* is currently having active urinary tract infection (UTI)\n* does not have any residual sensation in the arms\n* has other pain (musculoskeletal, visceral etc.), but not neuropathic, e.g., shoulder pain from wheelchair use\n* has a pacemaker to avoid possible side effect of electrical stimulation\n* is not able to follow commands, or to give consent\n* has asthma or other pulmonary disease\n* has a history of cardiac pathology, implanted pacemakers, or current use of rhythm altering medication like beta-blockers\n* has baclofen pump or deep brain implants\n* has respiratory tract\u002Fsinus infection and rhinorrhea\n* has low motor neuron injury that no responses will be triggered by electrical stimulation\n* has severe mental disorders (e.g., depression, substance abuse) and is receiving active treatment and frequent monitoring\n* is not medically stable","22 Years","80 Years",{"count":307,"type":20},[23],"The purpose of this study is to compare the effectiveness of innovative intervention of breathing controlled electrical stimulation (BreEStim) and sham BreEStim and Transcutaneous Electrical Nerve Stimulation (TENS) in management of neuropathic pain in patients after spinal cord injury (SCI).",[431],"Pain Management",[433,434],"neuropathic pain","BreEStim","2026-07-29",{"date":437,"type":35},"2026-07-31",{"date":141,"type":20},{"date":440,"type":20},"2029-09-30",{"name":41,"class":42},{"id":443,"slug":444,"hasResults":12,"nctId":445,"briefTitle":446,"officialTitle":447,"acronym":4,"eligibilityCriteria":448,"healthyVolunteers":12,"sex":16,"minAge":71,"maxAge":4,"enrollmentInfo":449,"targetDuration":450,"studyType":451,"phases":4,"briefSummary":452,"conditions":453,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":455,"lastUpdatePostDateStruct":456,"startDateStruct":457,"completionDateStruct":459,"leadSponsor":461,"locationsCount":43},"100649552","safety-and-efficacy-of-endoscopic-ultrasound-eus-guided-radiofrequency-ablation-rfa-in-the-treatment-of-pancreatic-lesions-100649552","NCT07737171","Safety and Efficacy of Endoscopic Ultrasound (EUS) Guided Radiofrequency Ablation (RFA) in the Treatment of Pancreatic Lesions","Safety and Efficacy of Endoscopic Ultrasound (EUS) Guided Radiofrequency Ablation (RFA) in the Treatment of Pancreatic Lesions: A Pancardinal-4 Prospective Registry","Inclusion Criteria:\n\n* Diagnosis of any pancreatic pre-malignant lesion and\u002For pancreatic malignancy\n* Patients already undergoing EUS-RFA for treatment of pancreatic lesions clinically\n\nExclusion Criteria:\n\n* Patients with co-existing malignancies of other organs (or a prior history of such)\n* Patients unable to provide informed consent\n* Patients unable to complete follow-up",{"count":19,"type":20},"3 Years","OBSERVATIONAL","This is a 7-year prospective single-center registry study to assess the safety and efficacy of Endoscopic Ultrasound (EUS) Guided Radiofrequency Ablation (RFA) in the treatment of pancreatic lesions.",[454],"Pancreatic Cancer","2026-07-27",{"date":392,"type":35},{"date":458,"type":35},"2026-04-07",{"date":460,"type":20},"2033-04-01",{"name":41,"class":42},{"id":463,"slug":464,"hasResults":12,"nctId":465,"briefTitle":466,"officialTitle":467,"acronym":4,"eligibilityCriteria":468,"healthyVolunteers":12,"sex":16,"minAge":71,"maxAge":4,"enrollmentInfo":469,"targetDuration":4,"studyType":21,"phases":470,"briefSummary":471,"conditions":472,"keywords":474,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":455,"lastUpdatePostDateStruct":476,"startDateStruct":477,"completionDateStruct":479,"leadSponsor":481,"locationsCount":43},"100438540","phase-2-eus-rfa-pancardinal-1-trial-100438540","NCT04990609","EUS-RFA PANCARDINAL-1 Trial","A Single-arm Phase II Study to Evaluate the Safety and Efficacy of Combination Systematic Chemotherapy and Multiple Rounds of Endoscopic Ultrasound-guided Radiofrequency Ablation in Pancreatic Cancer","Inclusion Criteria:\n\n* Diagnosed and histologically-confirmed PDAC by biopsy\n* Permanent street address\n* Consent to study participation\n* Axial CT scan consistent with PDAC\n* No prior chemotherapy or less than 2 months of pre-operative chemotherapy for PDAC\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2\n\nExclusion Criteria:\n\n* Male or female patients \\\u003C 18 years of age\n* No permanent street address or telephone number\n* Pregnant patients\n* Inmates or prisoners\n* Unable to provide informed consent",{"count":19,"type":20},[211],"The objectives of this study are to determine the feasibility, tolerability, and treatment effect of endoscopic ultrasound (EUS) radiofrequency ablation (RFA) plus standard-of-care neoadjuvant chemotherapy (NAC) in the treatment of pancreatic ductal adenocarcinoma (PDAC). Endoscopic ultrasound (EUS) radiofrequency ablation (RFA) and neoadjuvant chemotherapy (NAC) will be performed before tumor resection surgery, with the goal of shrinking a tumor or stopping the spread of cancer so that surgery might be less invasive and more effective.",[473],"Pancreatic Ductal Adenocarcinoma (PDAC)",[475],"Endoscopic Ultrasound Radiofrequency ablation (EUS-RFA)",{"date":435,"type":35},{"date":478,"type":35},"2021-08-13",{"date":480,"type":20},"2028-05-30",{"name":41,"class":42},{"id":483,"slug":484,"hasResults":12,"nctId":485,"briefTitle":486,"officialTitle":487,"acronym":488,"eligibilityCriteria":489,"healthyVolunteers":12,"sex":16,"minAge":490,"maxAge":51,"enrollmentInfo":491,"targetDuration":4,"studyType":21,"phases":492,"briefSummary":493,"conditions":494,"keywords":496,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":498,"lastUpdatePostDateStruct":499,"startDateStruct":500,"completionDateStruct":501,"leadSponsor":503,"locationsCount":43},"100649315","tolerability-of-transcutaneous-vagal-nerve-stimulation-100649315","NCT07735234","Tolerability of Transcutaneous Vagal Nerve Stimulation","Tolerability of Transcutaneous Auricular Vagus Nerve Stimulation in Pediatric Stroke Survivors 1Tolerability of Transcutaneous Auricular Vagus Nerve Stimulation in Pediatric Stroke Survivors 1","TAPSS-1","Inclusion Criteria:\n\n* Childhood stroke survivor - either arterial ischemic stroke or intracerebral hemorrhage.\n* Stroke must be childhood onset, defined as occurring day 29 of life to 18 years of age (per the American Heart Association's definition of childhood stroke)\n* 6 months or greater from stroke onset\n* Arm impairment, defined as pediatric stroke outcome measure of 1 or greater of affected arm.\n* Affected arm Fugl-Meyer score of 60 or lower.\n* Able to participate in occupational therapy sessions.\n\nExclusion Criteria:\n\n* Craniectomy without replacement of bone flap. Patients who underwent craniectomy will need the bone flap reattached prior to participation.\n* Presence of cranial metal implants or implant device that could be affected by taVNS: cochlear implant, implanted brain stimulator, or programmable ventriculoperitoneal shunt.","13 Years",{"count":43,"type":20},[23],"The purpose of this study is to assess the feasibility and tolerability of transcutaneous auricular vagus nerve stimulation (taVNS) in childhood stroke survivors undergoing bi-manual occupational therapy.",[495],"Stroke",[497],"childhood stroke","2026-07-24",{"date":435,"type":35},{"date":392,"type":20},{"date":502,"type":20},"2026-09-04",{"name":41,"class":42},{"id":505,"slug":506,"hasResults":12,"nctId":507,"briefTitle":508,"officialTitle":509,"acronym":4,"eligibilityCriteria":510,"healthyVolunteers":12,"sex":16,"minAge":71,"maxAge":208,"enrollmentInfo":511,"targetDuration":4,"studyType":21,"phases":512,"briefSummary":513,"conditions":514,"keywords":516,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":520,"lastUpdatePostDateStruct":521,"startDateStruct":523,"completionDateStruct":524,"leadSponsor":526,"locationsCount":43},"100647833","phase-2-zavegepant-intranasal-spray-for-the-acute-treatment-of-episodic-cluster-headache-100647833","NCT07714369","Zavegepant Intranasal Spray for the Acute Treatment of Episodic Cluster Headache","Zavegepant Intranasal Spray for the Acute Treatment of Episodic Cluster Headache: A Prospective, Open-Label, Single-Arm, Interventional Pilot Study","Inclusion Criteria:\n\n* A diagnosis of episodic cluster headache according to the International Classification of Headache Disorders 3rd edition\n* A history of at least 2 prior headache bouts\n* Onset of cluster headache before age 50 years\n* Cluster headache attacks last a minimum duration of 45 minutes (if untreated)\n* Evidence of signed informed consent (ICF) as described in the protocol, indicating compliance with the requirements and restrictions listed in the ICF and this protocol\n\nExclusion Criteria:\n\nGeneral exclusions\n\n* Pregnant or breastfeeding patients.\n* Inability to follow training instructions for use of nasal device.\n* Unable to speak or read English.\n* Unable to access the internet (for the Questionnaires \u002F Case Report Forms).\n* Females of childbearing potential, without the ability to use 2 acceptable methods of contraception to avoid pregnancy for up to 48 hours after each study drug administration, followed by 1 acceptable method for 28 days after the last administration of study treatment.\n* Body mass index ≥ 35 kg\u002Fm2\n* Prisoners or subjects who are involuntarily incarcerated.\n* Subjects who are compulsorily detained for treatment of either a psychiatric or physical (e.g., infectious disease) illness.\n* Have participated in another clinical research study with biological investigational agents (or other relevant agents) in the last 90 days.\n* Positive drug screen for drugs of abuse at the investigator's discretion (e.g., positive amphetamines may be allowed when prescribed for an approved indication such as ADHD)\n\nPast medical history exclusions:\n\n* Co-existing disease or other characteristics that precludes appropriate diagnosis of cluster headache. Other headache and facial pain disorders are allowed as long as their attacks are distinguishable from cluster headache attacks\n* Currently uncontrolled, unstable, or recently diagnosed cardiovascular or neurovascular disease, Raynaud's disease, uncontrolled hypertension, a history of myocardial infarction , Acute Coronary Syndrome (ACS), Percutaneous Coronary Intervention (PCI), cardiac surgery, stroke or Transient Ischemic Attack (TIA) in the prior 6 months\n* A known history of severe hepatic impairment, or diagnosis of Gilbert's Syndrome or any other active hepatic or biliary disorder\n* A history of Human Immunodeficiency Virus (HIV).\n* Active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements\n* Response of \"yes\" to Question 4 or 5 for suicidal ideation, or any suicidal behavioral question on the Columbia Suicide Severity Rating Scale (C-SSRS) at screening (or up to 1 year prior to the screening, as assessed in the medical history), or any indication of serious risk of suicide in the opinion of the investigator\n* Psychiatric disorders that, in the opinion of the site investigator, would interfere with adherence to study requirements. This includes participants who have confirmed but untreated psychiatric disorders, or have psychiatric disorders that, in the opinion of the site investigator, would make them unable to undergo an ECG, have laboratory testing, or administer the medication at the appropriate time. \"Psychiatric disorders\" refers specifically to the following Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) classes of disorders: Schizophrenia Spectrum and Other Psychotic Disorders, Bipolar and Related Disorders, Depressive Disorders, Anxiety Disorders, Obsessive-Compulsive and Related Disorders, Trauma- and Stressor-Related disorders, Dissociative Disorders, Somatic Symptom and Related Disorders, Feeding and Eating Disorders, Disruptive, Impulse-Control and Conduct Disorders, Substance-Related and Addictive Disorders, or Neurocognitive Disorders\n* Hematologic or solid malignancy diagnosis within 5 years prior to the screening visit. Subjects with a history of localized basal cell or squamous cell skin cancer are eligible for the study if they are cancer-free prior to the screening visit\n\nNasal issues\n\n* History of nasal surgery in the 6 months preceding the screening visit\n* Nose piercings that might interfere with positioning of the study medication\n* Evidence at screening of significant nasal conditions that may affect the administration or absorption of the nasal product (e.g., severe septum deviation, nasal deformity or blockage, inflammation, perforation, mucosal erosion or ulceration, polyposis, nasal trauma) as evaluated by the Investigator or medically qualified delegate\n* Prominent nasal congestion or rhinorrhea associated with cluster headache attacks that, in the opinion of the study team, will interfere with ipsilateral absorption of a nasal spray\n\nLaboratory and ECG abnormalities within 3 months of screening including:\n\n* ECG abnormalities including Corrected QT interval (QTc) \\> 470 msec, Left Bundle Branch Block (LBB), Right Bundle Branch Block (RBB) with QRS\\>150 msec, or Intraventricular Conduction Defect with a QRS duration ≥ 150 msec\n* History of stage 4 renal disease (creatinine clearance\\\u003C30 mL\u002Fmin)\n* Any unacceptable findings on laboratory studies or physical examination including bilirubin \\>1.5x upper limit of normal(ULN), Neutrophil count ≤ 1000\u002FuL (or equivalent), Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) \\>1.5x ULN\n* Uncontrolled diabetes, defined as HbA1c ≥ 7.5%\n\nZavegepant-specific exclusions\n\n* History of hypersensitivity reaction to zavegepant or to any of the components of zavegepant\n* Previous use of zavegepant, or previously intolerant of zavegepant (if tried for noncluster headache reasons)\n* Concomitant use of potent inhibitors\u002Finducers of Organic Anion Transporting Polypeptide 1B3 (OATP1B3) or Sodium\u002FTaurocholate Cotransporting Polypeptide (NTCP) transporters including atazanavir, clarithromycin, cyclosporine, estrone sulfate, lopinavir, gemfibrozil, rifampin, or ritonavir",{"count":184,"type":20},[211],"The purpose of this study is to assess headache response rate for minimal pain at 30 minutes following zavegepant administration and to assess additional effectiveness and treatment failure endpoints at various timepoints after zavegepant administration",[515],"Cluster Headache",[517,518,519],"Zavegepant","headache","CGRP","2026-07-14",{"date":522,"type":35},"2026-07-20",{"date":141,"type":20},{"date":525,"type":20},"2028-05-01",{"name":41,"class":42},{"id":528,"slug":529,"hasResults":12,"nctId":530,"briefTitle":531,"officialTitle":532,"acronym":533,"eligibilityCriteria":534,"healthyVolunteers":12,"sex":16,"minAge":535,"maxAge":4,"enrollmentInfo":536,"targetDuration":4,"studyType":21,"phases":537,"briefSummary":538,"conditions":539,"keywords":541,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":544,"startDateStruct":546,"completionDateStruct":548,"leadSponsor":550,"locationsCount":43},"100601582","phase-4-the-fintepla-as-an-anti-sudep-therapy-in-dravet-syndrome-project-100601582","NCT07112365","The FINTEPLA as an Anti-SUDEP Therapy in Dravet Syndrome Project","The FINTEPLA as an Anti-SUDEP Therapy in Dravet Syndrome (FAST-DS) Project.","FAST-DS","Inclusion Criteria:\n\n* DS patients (with or without SCN1A pathogenic mutations)\n* Generalized convulsive seizures\n\nExclusion Criteria:\n\n* known cardiorespiratory, hepatic or renal disease, and\u002For\n* allergic reactions or other contraindications to fenfluramine and\u002For\n* on Stiripentol treatment, and\u002For\n* on serotonergic medications, and\u002For\n* contraindications to Midazolam anesthesia\n* taken the following drugs within 14 days: monoamine oxidase inhibitors (MAOIs), anti-depressants (Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin and norepinephrine reuptake inhibitors (SNRIs), and Tricyclic antidepressants (TCAs)), St. John's Wort, Tryptophan, and Dextromethorphan","16 Years",{"count":7,"type":20},[102],"This study investigates cerebrovascular reactivity (CVR) and functional brain connectivity in Dravet Syndrome (DS) patients with convulsive seizures. Using functional MRI (fMRI), we will define differences in brain responses to CO₂ changes before administration of the drug Fintepla (Baseline), with a library of healthy controls and with those obtained after administration of Fintepla (Day \\~60). Changes in CVR and their relation to ventilatory responses will also be assessed during fMRI.",[540],"Dravet Syndrome",[542,543],"epilepsy","Sudden Unexpected Death in Epilepsy (SUDEP)",{"date":545,"type":35},"2026-07-15",{"date":547,"type":35},"2026-04-27",{"date":549,"type":20},"2028-03-31",{"name":41,"class":42},{"id":552,"slug":553,"hasResults":12,"nctId":554,"briefTitle":555,"officialTitle":555,"acronym":4,"eligibilityCriteria":556,"healthyVolunteers":12,"sex":16,"minAge":71,"maxAge":557,"enrollmentInfo":558,"targetDuration":4,"studyType":21,"phases":560,"briefSummary":561,"conditions":562,"keywords":565,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":567,"lastUpdatePostDateStruct":568,"startDateStruct":569,"completionDateStruct":571,"leadSponsor":573,"locationsCount":43},"100515314","mapping-of-human-cognition-100515314","NCT05989893","Mapping of Human Cognition","Inclusion Criteria:\n\n* patients with medically refractory epilepsy who are scheduled to undergo or have previously undergone placement of sub-dural electrodes (including depth electrodes) to localize the site of seizure onset and to map the locations of critical language and motor regions\n* patients with epilepsy, brain tumors or cortically based vascular malformations (cavernous malformations or arterio-venous malformations) with lesions that are\u002Fwere proximate to crucial brain regions, and who are scheduled to undergo or have previously undergone intra-op mapping of motor, visual or language function, or a Wada test, or maybe part of an awake craniotomy.\n* proficiency in English\n\nExclusion Criteria:\n\n* Gross structural abnormalities (large hamartomata, tumors, large vascular malformations, very large diffuse malformations of cortical development) that may have impacted upon the location of critical brain areas.\n* Unable to participate in testing due to impaired cognition or mental retardation.\n* Cardiac pacemakers, intracranial aneurysm clips, or other potentially mobile implanted metallic devices\n* Patients with claustrophobia who cannot undergo an MRI scan without sedation","75 Years",{"count":559,"type":20},75,[23],"The purpose of this study is to compare organization of normal brain function as detected using Functional magnetic resonance imaging (fMRI) in normal subjects as opposed to patients with epilepsy or brain tumors, to ascribe precise anatomic labels (including Brodmann Areas) and functional significance to each region involved in cognitive processes as detected by cortical stimulation mapping (CSM) in patients with implanted subdural electrodes (SDE) or depth (sEEG) electrodes, to describe the locations of these regions in Talairach space, for a population of patients without overt structural abnormalities in these regions, to generate a spatial probability map of locations of cortical regions \"essential\" for these processes, to compare the loci of \"crucial\" language, visual, motor and cognitive sites as determined by CSM with the loci determined by a battery of tasks using fMRI for each individual and to use these data in patients undergoing intracranial electro-corticographyto determine the loci of essential, involved and uninvolved brain areas, and use sophisticated mathematical analyses of these intracranial recordings to study information flow between these areas.",[563,564],"Epilepsy","Brain Tumor",[566],"seizure","2026-07-10",{"date":520,"type":35},{"date":570,"type":35},"2022-08-01",{"date":572,"type":20},"2028-07-31",{"name":41,"class":42},{"id":575,"slug":576,"hasResults":12,"nctId":577,"briefTitle":578,"officialTitle":578,"acronym":4,"eligibilityCriteria":579,"healthyVolunteers":12,"sex":580,"minAge":71,"maxAge":4,"enrollmentInfo":581,"targetDuration":4,"studyType":21,"phases":583,"briefSummary":584,"conditions":585,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":587,"lastUpdatePostDateStruct":588,"startDateStruct":589,"completionDateStruct":591,"leadSponsor":593,"locationsCount":43},"100537264","accelerating-healthcare-engagement-in-healthy-food-interventions---food-rx-in-high-risk-pregnant-mothers-with-about-fresh-and-community-health-choice-100537264","NCT06275568","Accelerating Healthcare Engagement in Healthy Food Interventions - Food Rx in High Risk Pregnant Mothers With About Fresh and Community Health Choice","Inclusion Criteria:\n\n* Less than or equal to 20 weeks medically confirmed viable pregnancy\n* high-risk pregnant mothers receiving care at Community Health Choice managed care organizations in Houston, Texas (High risk may include overweight\u002Fobese pre-pregnancy or at first trimester (self-report or measured BMI\\>30.0), and\u002For prior history of diabetes or gestational diabetes, and\u002For prior history of hypertension or pregnancy-induced hypertension)\n\nExclusion Criteria:\n\n* Does not Speak English or Spanish","FEMALE",{"count":582,"type":20},620,[23],"The purpose of the study is to assess if the Fresh Connect food prescription (Fresh Connect Food Rx) program that provides consistent access to healthy fresh produce through purchases at the grocery store plus nutrition education impacts gestational weight gain, other pregnancy and birth outcomes, and food and nutrition security in low-income, ethnically diverse, at-risk women residing in Houston, Texas. Enrollment of participants will begin in pregnancy at the time of the first prenatal visit (as long as the first visit occurs before the end of the first trimester); each participant will be followed until 60 days post-partum (up to 11 months follow-up per participant).",[586],"Nutrition in High-Risk Pregnancy","2026-07-09",{"date":37,"type":35},{"date":590,"type":35},"2025-07-03",{"date":592,"type":20},"2027-12-01",{"name":41,"class":42},{"id":595,"slug":596,"hasResults":12,"nctId":597,"briefTitle":598,"officialTitle":598,"acronym":4,"eligibilityCriteria":599,"healthyVolunteers":12,"sex":16,"minAge":71,"maxAge":207,"enrollmentInfo":600,"targetDuration":4,"studyType":21,"phases":602,"briefSummary":603,"conditions":604,"keywords":606,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":608,"lastUpdatePostDateStruct":609,"startDateStruct":610,"completionDateStruct":611,"leadSponsor":613,"locationsCount":43},"100606024","navigating-the-transition-to-adulthood-a-dual-language-mobile-app-for-latino-youth-with-asd-and-their-families-100606024","NCT07170163","Navigating the Transition to Adulthood: A Dual Language Mobile App for Latino Youth With ASD and Their Families","Inclusion Criteria:\n\n* Latino young adults with ASD ASD with a score of 15 or greater on the Social Communication Questionnaire-Lifetime (SCQ-L)\n* meets Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR), criteria for ASD based on a DSM-5-TR ASD symptom checklist\n* previous diagnosis of ASD from a licensed mental health or medical professional(f they have not been diagnosed by a licensed mental health or medical professional, a complete a diagnostic evaluation will be conducted, using semi-structured interviews, questionnaires, the autism diagnostic interview-revised (ADI-R), and the Autism Diagnostic Observation Schedule, Second Edition (ADOS-2) to confirm ASD diagnosis)\n* above the \"moderate\" cut off for symptoms of anxiety or depression( Depression and anxiety symptoms will be assessed via the Patient Health Questionnaire-9 (PHQ-9) and the Generalized Anxiety Disorder-7 (GAD-7)\n* Spanish-speaking parents\n\nExclusion Criteria:\n\n* low intelligence quotient (IQ) score (Verbal IQ \\\u003C 70) on the verbal IQ on Kaufman Brief Intelligence Test Second Edition (KBIT-2)\n* psychotic as determined by the Structured clinical interview for Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM5): Research Version (SCID-5-RV), or are actively suicidal with an active plan.\n* substance abuse",{"count":601,"type":20},30,[23],"The purpose of this study is to determine useability and satisfaction characteristics,product usage data,methodological feasibility parameters and feasibility metrics of the mHealth app adapted intervention on the mental health, quality of life, and adaptive functioning of Latino transition aged young adults with ASD and their parents.",[605],"Autism Spectrum Disorder (ASD)",[607],"mHealth app","2026-07-08",{"date":567,"type":35},{"date":364,"type":20},{"date":612,"type":20},"2027-06-30",{"name":41,"class":42},""]